Fig. 8: The IC50 determination of the inhibition of MH and the positive control, haloperidol, in σ1. | npj Parkinson's Disease

Fig. 8: The IC50 determination of the inhibition of MH and the positive control, haloperidol, in σ1.

From: Repurposing the memory-promoting meclofenoxate hydrochloride as a treatment for Parkinson’s disease through integrative multi-omics analysis

Fig. 8

A The IC50 of the positive control (Haloperidol) in inhibiting the σ1. Eight different concentrations of haloperidol were tested. B The IC50 of MH in inhibiting the σ1. Eight different concentrations of MH were tested. C IHC representation of σ1 receptor expression across different groups.

Back to article page